REYKJAVIK, Iceland — November 4, 2025 — Leads & Copy — Alvotech (NASDAQ: ALVO) will release its financial results for the first nine months of 2025, ending September 30, after U.S. markets close on Wednesday, November 12, 2025. A conference call to present the results will be held on Thursday, November 13, 2025, at 8:00 am EST. Management will provide a business update, including the status of pending approvals in the U.S. and Europe. Live audio of the conference call will be webcast and a recording made available on Alvotech’s investor portal.
Information on accessing the webcast or participating by conference call is available at https://investors.alvotech.com/events/event-details/q3-2025-earnings. An audio recording of the webcast will be archived for 90 days after the event.
Alvotech, founded by Robert Wessman, focuses on developing and manufacturing biosimilar medicines. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab), are already approved and marketed globally. The pipeline includes nine disclosed biosimilar candidates for autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has strategic commercial partnerships for global reach, including with Teva Pharmaceuticals, STADA Arzneimittel AG, and Fuji Pharma Co.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS:
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
Source: Alvotech
